Please, Signup (Login) to subscribe or trade (demo)
Astrazeneca PLC stock price
Astrazeneca PLC latest news:
UK Stocks-Factors to watch on Feb 19
Feb 19 (Reuters) - Britain's FTSE 100 index is seen opening 12
points higher at 7,306.4 on Monday, according to financial bookmakers.
* ASTRAZENECA: The U.S. Food and Drug Administration on Friday granted
approval for expanded use of AstraZeneca Plc's immunotherapy
drug, Imfinzi, to treat non-small cell lung cancer whose tumors can't be
* ACACIA MINING: Gold miner Acacia Mining confirmed on Friday it
had begun to value its Tanzanian operations for a potentia
U.S. FDA approves AstraZeneca's immunotherapy for lung cancer
The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc's (AZN), immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumors can't be surgically removed. The approval was based on a trial testing on 713 patients whose cancer had not progressed after chemotherapy and radiation.
AstraZeneca flags return to drug sales growth in 2018
LONDON, Feb 2 (Reuters) - AstraZeneca expects to
increase drug sales at a low single-digit percentage rate this
year as new medicines win market share and the company puts
patent losses behind it, although the need to invest in launches
will weigh on profit.
AstraZeneca is sued by Array BioPharma over cancer drug royalties
Array BioPharma Inc(ARRY) on Thursday sued AstraZeneca AB, accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 billion collaboration with Merck & Co. In a complaint filed in the New York State Supreme Court in Manhattan, Array is seeking at least $192 million from AstraZeneca (AZN) for the alleged breach of a 2003 licensing agreement relat...
UPDATE 1-UK Stocks-Factors to watch on Jan 26
(Adds company news item, futures)
Jan 26 (Reuters) - Britain's FTSE 100 index is seen opening 23
points higher at 7,638.4 on Friday, according to financial bookmakers, with
futures up 0.20 percent ahead of the cash market open.
* ASTRAZENECA: AstraZeneca said its inhaler for chronic obstructive
pulmonary disease (COPD) showed improved lung function in a late stage trial
that could challenge GlaxoSmithKline's new three-in-one inhaler.
At AstraZeneca, fewer drug projects bring big productivity jump
LONDON (Reuters) - A focus on fewer diseases, together with cuts in laboratories and staff, has delivered a more than fourfold increase in research productivity at drugmaker AstraZeneca , based on one key measure of success. The analysis published on Friday comes at a time of soul-searching among large pharmaceutical companies as they compete with smaller biotech firms, which are getting new drugs to market more efficiently. The turnaround evident this decade at AstraZeneca fo
Top Analyst Upgrades and Downgrades: American Water Works, JB Hunt, Ford, GM, AstraZeneca and More
BRIEF-US FDA Accepts Tagrisso Submission For 1St-Line Nsclc
Astrazeneca Plc(AZN): * FDA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLC. * US FDA ACCEPTS REGULATORY SUBMISSION FOR TAGRISSO IN 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER Source text for Eikon: Further company coverage:
AstraZeneca steps up China push with new drug joint venture
LONDON (Reuters) - Drugmaker AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a state-backed private equity fund.
Atlantic Power CorporationAT
Atlas Resource PartnersARP
Atlas Resource PartnersARP^D
Atlas Resource PartnersARP^E
Atmos Energy CorporationATO
AU Optronics CorpAUO